Feb 06, 2018 - Names on the move ahead of the open.
Feb 06, 2018 - Includes detailed analysis of Barrage Capital Fund's positions in CHTR, AMZN, BT, AGN, C, GM, AN, AIG, BCS.In 2017, the S&P/TSX index generated a return of 9.02% (including dividends), while the S&P 5
Feb 06, 2018 - Today, I am going to do something we rarely do. I will share a large excerpt from IMA's last quarterly letter to clients. Our quarterly letters are somewhat unconventional in that they provide an in-d
Feb 06, 2018 - Allergan (AGN) beats expectations for both earnings and revenues in Q4. A phase III study evaluating Allergan's migraine candidate, ubrogepant meets its co-primary endpoints.
Feb 05, 2018 - AGN reports Q4 earnings Tuesday.The company faces patent losses for Restasis, Combigan and Estrace. They represent a combined 15% of total revenue.LOE and a potential decline in sentiment could sink A
Feb 05, 2018 - Explains the equity multiplier and the debt ratio and demonstrates that the way we use them is all wrong.Enumerates some of the costs and risks of equity funding.Problematizes using book value as a fo
Feb 05, 2018 - Fishman Jay A Ltd Buys Intel Corp, Lennar Corp, General Motors Co, Sells Allergan PLC, Celgene Corp, Starbucks Corp, Stocks: INTC,LEN,GM,EXP,BAC,IBB,F,VV,SU,AGN,SBUX,CVS,NWL,C, release date:Feb 05, 2018
Feb 05, 2018 - TEVA received $700MM from AGN to settle a dispute related to the acquisition of AGN's generics business.TEVA's credit metrics and share price will likely deteriorate despite the payment.TEVA remains a
Feb 04, 2018 - What Can We Do Now? Part II, Stocks: AGN,BRK.B,DHR,DJCO,GOOGL,KHC,MKL,PEP, Howard Marks,Charlie Munger, release date:Feb 04, 2018
Feb 03, 2018 - The biotech sector is plummeting with the rest of the market this week trapped within a 'hiccup' that hits equities from time to time. The sector is basically given back last week's large gains and th